英菲格拉替尼显示出治疗FGFR2改变的晚期胆管癌的潜力

Cholangiocarcinoma is a malignant tumor originating from the bile duct epithelium. Although its incidence is low, cholangiocarcinoma is the second most common primary malignant tumor of the liver after liver cancer. Overall, approximately 5% to 10% are located within the liver, 60% to 70% are located around the liver portal, and 20% to 30% are located outside the liver. In hilar cholangiocarcinoma, only 20% to 30% of patients can undergo radical surgical resection, and most patients can only receive palliative treatment. Since hilar cholangiocarcinoma is dominated by local complications rather than metastatic disease, local palliative treatment seems to be a reasonable option. Infigratinib showed potential in treating advanced cholangiocarcinoma with FGFR2 alterations in a trial that showed "promising" clinical activity in previously treated patients with advanced cholangiocarcinoma with FGFR2 fusions or rearrangements, researchers report in The Lancet Gastroenterology and Hepatology.

From May 29 to 31, 2020, at the 2020 American Society of Clinical Oncology Annual Meeting (ASCO) held in Chicago, the United States, the R&D company released some of the results of the Phase II clinical study of Infigratinib. This study is a multi-center, single-group clinical study that included 71 subjects to evaluate the efficacy of infigratinib as a third-line or above treatment for patients with FCFR2 fusion-positive cholangiocarcinoma.

The results showed that in the case of second-line treatment, the median progression-free survival (PFS) of patients was 4.63 months; the median PFS of patients who received third-line and above treatment with infigratinib was 6.77 months. The objective response rate (ORR) of patients receiving third-line or above treatment was 21.6%.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.